Links de passagem do livro para 5.1.3 Haematological assessment
Due to the risk of myelosuppression associated with even relatively short exposures to linezolid, pretreatment assessment of haemoglobin, neutrophils and platelets is crucial in patients considering treatment with a linezolid-containing regimen. Severe anaemia in patients with TB is a significant risk factor for poor treatment outcomes (48), and patients with a low baseline haemoglobin may be at risk of severe linezolid-induced haematological toxicity. The linezolid-containing 9-month regimen must not be offered to patients with a pretreatment serum haemoglobin below 8 g/dL that cannot be rapidly corrected (i.e. with a blood transfusion) before starting MDR/RR-TB treatment. Similarly, due to the morbidity associated with severe neutropenia and thrombocytopenia, the linezolid-containing 9-month regimen is not suitable in patients with neutrophils below 0.75 × 109/L or platelets below 150 × 109/L before starting treatment.